Company Overview - NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company’s RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source, aiming to improve care for patients with drug-resistant epilepsy [3] Upcoming Events - NeuroPace's management team will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 4:20pm ET in Miami, FL, and will also host investor meetings during the conference [1] - The presentation will be accessible via live webcast, with a replay available for two weeks following the event on NeuroPace's Investor website [2]

Company Overview - NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company has developed the RNS System, which is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3] Upcoming Events - NeuroPace's management team will present at the Leerink Partners 2025 Global Healthcare Conference on January 10, 2025, at 4:20 PM ET in Miami, FL [1] - The presentation will be accessible via live webcast, with a replay available for two weeks following the event on NeuroPace's Investor website [2]

Company Overview - NeuroPace, Inc. (NPCE) shares increased by 5.8% to $14.23 in the last trading session, following a higher-than-average trading volume, contrasting with a 4.2% loss over the past four weeks [1] - The company is set to release its fourth-quarter 2024 financial results on March 4, 2025, after the market closes [2] Financial Performance Expectations - The Zacks Consensus Estimate anticipates a revenue growth of 19.2% for the fourth quarter, projecting revenues of $21.46 million compared to the same quarter last year [2] - The expected quarterly loss is $0.25 per share, reflecting an 8.7% decrease year-over-year [2] Earnings Estimate Trends - The consensus EPS estimate for NeuroPace has remained unchanged over the last 30 days, indicating a lack of upward revisions which typically correlate with stock price movements [4] - The stock's recent price increase may not sustain without a trend in earnings estimate revisions, suggesting the need for close monitoring of NPCE's performance [4] Industry Context - NeuroPace operates within the Zacks Medical - Instruments industry, where Tandem Diabetes Care, Inc. (TNDM) also resides, having closed 1.3% higher at $32.12, but with a -9.4% return over the past month [4] - Tandem Diabetes Care's consensus EPS estimate has remained unchanged at -$0.21, representing a 22.2% increase compared to the previous year's EPS [5]

Core Insights - NeuroPace, Inc. has completed the repurchase of 5,270,845 shares from KCK Ltd., allowing KCK to sell all remaining shares it held in the company [1] - The repurchase was funded using proceeds from a recent underwritten public offering, which has strengthened NeuroPace's balance sheet and is expected to support operations until cash flow breakeven is achieved [1][2] - The company has terminated its current at-the-market offering program following the completion of the public offering [1] Financial Position - The recent financing has provided sufficient cash runway for NeuroPace to execute its long-range plan and achieve cash flow breakeven [2] - The company expressed gratitude to KCK Ltd. for its support over the years [2] Product and Market Focus - NeuroPace is dedicated to transforming the lives of individuals with epilepsy through its RNS System, which is the first commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - The RNS System aims to improve care standards for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3]

Company Overview - NeuroPace, Inc. is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy by reducing or eliminating debilitating seizures [3] - The company has developed the RNS System, which is the first and only commercially available brain-responsive platform that delivers personalized, real-time treatment at the seizure source [3] - This platform aims to improve the standard of care for patients with drug-resistant epilepsy and has potential applications for other brain disorders [3] Financial Reporting - NeuroPace will report its financial results for the fourth quarter and full year of 2024 after market close on March 4, 2025 [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results [1] Investor Engagement - Investors can access the conference call via a live and archived webcast [2] - For those wishing to participate by telephone, the call can be accessed by dialing +1-877-407-3982 and referencing Conference ID 13751530 [2] - The webcast will be available for replay for at least 90 days after the event [2]

Core Viewpoint - NeuroPace, Inc. has successfully completed a public offering of 7,475,000 shares at a price of $10.00 per share, raising approximately $74.8 million in gross proceeds [1][2] Group 1: Offering Details - The offering included 975,000 shares sold due to the underwriters' full exercise of their option to purchase additional shares [1] - The net proceeds will be used primarily to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at $9.40 per share [2] - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, and working capital [2] Group 2: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners served as joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3] - The shares were offered under a shelf registration statement effective since November 22, 2022, with a final prospectus supplement filed with the SEC [4] Group 3: Company Overview - NeuroPace is a medical device company focused on improving the lives of individuals with epilepsy through its RNS System, which provides personalized, real-time treatment [6]

Core Viewpoint - NeuroPace, Inc. has announced a public offering of 6,500,000 shares at a price of $10.00 per share, aiming to raise approximately $65 million before expenses [1][2]. Group 1: Offering Details - The offering is expected to close on February 18, 2025, subject to customary closing conditions [1]. - NeuroPace has granted underwriters a 30-day option to purchase an additional 975,000 shares at the public offering price [1]. - The shares are being offered under a shelf registration statement filed with the SEC, effective since November 22, 2022 [4]. Group 2: Use of Proceeds - Approximately $49.5 million of the net proceeds will be used to repurchase 5,270,845 shares from significant stockholder KCK Ltd. at $9.40 per share [2]. - Remaining proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].

Core Viewpoint - NeuroPace, Inc. plans to offer $65 million in common stock through an underwritten public offering, with a potential additional 15% option for underwriters [1][2]. Group 1: Offering Details - The public offering consists of $65 million worth of common stock, all offered by NeuroPace [1]. - NeuroPace will grant underwriters a 30-day option to purchase up to an additional 15% of the shares [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - A significant portion of the proceeds will be used to repurchase shares held by KCK Ltd. at the same price per share as the public offering [2]. - Remaining net proceeds will be allocated for general corporate purposes, including clinical trials, research and development, administrative expenses, debt reduction, and working capital [2]. Group 3: Management and Registration - J.P. Morgan, Cantor, Wells Fargo Securities, and Leerink Partners are joint book-running managers for the offering, with Lake Street Capital Markets as the lead manager [3]. - The shares are being offered under a shelf registration statement effective since November 22, 2022, with a prospectus supplement to be filed with the SEC [4]. Group 4: Company Overview - NeuroPace is a medical device company based in Mountain View, California, focused on improving the lives of epilepsy patients through its RNS System, which provides personalized, real-time treatment [6].

Core Insights - NeuroPace, Inc. is focused on transforming the lives of individuals with epilepsy through innovative medical devices [3] - The company announced that an abstract from its Post-approval Study of the RNS System will be presented at the AAN 2025 Annual Meeting [1] Presentation Details - The presentation titled "Multicenter Post-approval Study of the RNS System in Focal Epilepsy" will be delivered by Dr. Dawn Eliashiv [2] - The session is scheduled for April 7, 2025, at 5:06 PM PT [2] Company Overview - NeuroPace is based in Mountain View, California, and specializes in developing the RNS System, which is the first commercially available brain-responsive platform for epilepsy treatment [3] - The RNS System aims to provide personalized, real-time treatment at the source of seizures, potentially improving care for patients with drug-resistant epilepsy [3]

– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually h ...